DIP Episode 8 - Comprehensive Heme Pharmacology

Source / episode info

• Episode: 8
• Title: Divine Intervention Episode 8 – Comprehensive Heme Pharmacology.
• Published: 2018-03-20
• Source: Episode page

One-liner

This episode comprehensively reviews hemostasis from the subendothelial collagen adhesion step through primary platelet aggregation, detailing the intrinsic and extrinsic coagulation cascades, and covering pharmacology of antiplatelet agents (aspirin, P2 Y12 inhibitors), NSAI Ds/COX-2 selective inhibitors, and anticoagulants (heparin, warfarin, C5 blockade).

High-yield summary

• Primary Hemostasis Defects: Bernard-Soulier syndrome involves defective GP1b/IX receptor (adhesion defect); Glanzmann thrombasthenia involves defective GPI Ib/II Ia receptor (aggregation defect); vWF deficiency impairs adhesion and prolongs bleeding time.
• Antiplatelet Agents: Aspirin irreversibly inhibits COX-1/COX-2, leading to reduced Thromboxane A2 ({TXA}_2) synthesis; selective COX-2 inhibitors (e.g., Celecoxib) reduce GI risk by sparing COX-1 function in the stomach.
• Anticoagulation Monitoring: Unfractionated Heparin is monitored via aPTT (both PTT and aPTT are elevated); Low Molecular Weight Heparin (LMWH) is monitored via Anti-Xa activity.
• PNH Pathophysiology: Deficiency of the GPI anchor leads to loss of complement inhibitors (CD55, CD59) on red blood cells, resulting in intravascular hemolysis. Treatment involves C5 blockade with Eculizumab.
• HIT Management: This is a Type II hypersensitivity reaction (IgG against Heparin-PF4 complex). Treatment requires direct thrombin inhibitors (e.g., Argatroban) or Factor Xa inhibitors (e.g., Rivaroxaban), never LMWH.

Learning objectives

• Differentiate between primary hemostasis defects (adhesion vs aggregation).
• Describe the molecular mechanism and clinical implications of various antiplatelet drugs (aspirin, COX inhibitors, P2 Y12 blockers).
• Compare the monitoring, mechanisms, and contraindications of different anticoagulants (Heparin, Warfarin, DOA Cs).
• Identify the pathophysiology and management of acquired thrombotic/hemorrhagic states (HIT, PNH, VWD).
• Understand the role of GPI anchors in cell surface proteins and complement regulation.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Differential diagnosis / distinguishing features

Anticoagulant-Induced Thrombocytopenia: HIT vs Drug-induced ITCP

Coagulation Factor Deficiencies: Hemophilia A vs B vs C vs VWD

Management pearls

• HIT Management: The cornerstone of therapy is stopping the offending agent (Heparin) and initiating a Factor Xa inhibitor (Rivaroxaban) or Direct Thrombin Inhibitor (Argatroban). Never restart LMWH.
• PNH Treatment: Use Eculizumab (C5 blockade) to prevent complement activation, which is triggered by hypoventilation/acidosis during sleep.
• GI Protection with NSAI Ds: For chronic aspirin use in high-risk patients (e.g., those needing antiplatelet therapy), co-administer a \text{PGE}_2 analog like Misoprostol to protect the gastric mucosa by bypassing COX inhibition.
• Peripheral Arterial Disease (PAD): The first-line treatment for symptomatic PAD is structured exercise/walking program, not vasodilators like Cilostazol or PDE inhibitors.

Don't miss

Integration & clinical reasoning

• Complement System & PNH: The complement cascade is the primary mechanism of hemolysis in PNH, specifically targeting cells lacking CD55/CD59. This links hematology (PNH) to immunology (complement deficiency).
• Vitamin K Cycle: Warfarin inhibits Vitamin K dependent factors (II, VII, IX, X). The cycle requires reduced Vitamin K for \gamma-carboxylation; the inhibition of recycling via VKORC is the mechanism of action.
• Acidosis/Alkalosis in PNH: Hypoventilation during sleep leads to respiratory acidosis (\downarrow pH), which activates complement and exacerbates hemolysis in PNH patients.

OMM / COMLEX integration

• Acute Bleeding: In any patient with acute, severe hemorrhage or suspected coagulopathy, standard emergency management (e.g., massive transfusion protocol, reversal agents) takes absolute priority over OMT. Coagulation factor replacement is a critical component of resuscitation.
• Thrombosis Risk: Patients undergoing major surgery or trauma are at high risk for venous thromboembolism (VTE). Prophylaxis often involves LMWH or unfractionated heparin, but the choice must be tailored to renal function and bleeding risk.

Concept connections / cross-references

• For detailed information on the coagulation cascade, see [Episode 37].
• For management of adrenal insufficiency (which can complicate bleeding/thrombosis workups), see [Episode 12].
• For understanding the role of prostaglandins in GI protection and vascular tone, see [Episode 45].

High-yield association table

Key terms glossary

Study optimization

Question pattern recognition

• The "Best Next Step" Question: Given a diagnosis (e.g., HIT), choose the most specific and safest treatment (DTI/Factor Xa inhibitor).
• Mechanism of Action Trap: Confusing irreversible vs reversible inhibition, or confusing which factor is targeted by an anticoagulant (e.g., Warfarin targets Vitamin K dependent factors II, VII, IX, X).
• Differential Diagnosis based on Lab Values: Using specific lab results (e.g., abnormal/decreased ristocetin-induced agglutination) to pinpoint the exact hemostasis defect.

Test yourself

Common mistakes to avoid

Common traps